English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background One- and two-dose mRNA vaccine effectiveness (VE) estimates against SARS-CoV-2 infection by dosing interval and time since vaccination were assessed among healthcare workers (HCWs) in publicly-funded acute and community (non-residential) healthcare facilities in British Columbia, Canada. Methods A test-negative design was used with (6:1) controls matched to cases on epidemiological week of SARS-CoV-2 test date. mRNA vaccination was defined by receipt of the first dose ≥21 days or second dose ≥14 days before test date. HCWs ≥18 years old tested for SARS-CoV-2 between epi-weeks 3-39 (January 17-October 2,2021) were included, when varying dosing intervals and a mix of circulating variants-of-concern contributed, including Delta dominance provincially from epi-week 31 (August 1). Results Single- and two-dose analyses included 1,265 and 1,246 cases, respectively. Median follow-up period was 49 days (interquartile range: 34-69) for single-dose and 89 days (interquartile range: 61-123) for two-dose recipients, with 12%, 31% and 58% of second doses given 3-5, 6 or ≥7 weeks after the first. Adjusted mRNA VE against SARS-CoV-2 was 71% [95% CI: 66, 76] for one dose and 90% [95% CI: 88, 92] for two doses, similar with two heterologous mRNA doses (92%;[95% CI: 86, 95]). Two-dose VE remained &amp;gt;80% at ≥28 weeks post-second dose. Two-dose VE was consistently 5-7% higher with ≥7-week versus 3-5-week interval between doses. Conclusions In a HCW population, we report substantial single-dose and strong and sustained two-dose mRNA vaccine protection, the latter maintained at least seven months. Findings inform longer interval between doses, with global health and equity implications.

open forum infectious diseases

SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada